Marvin & Palmer Associates’s AbbVie ABBV Stock Holding History

Marvin & Palmer Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,848	Closed	-$3.13M	–	28
2024 Q3	$3.13M	Buy	+15,848	New	+$2.96M	2.62%	17
2014 Q2	–	Sell	-20,555	Closed	-$1.06M	–	68
2014 Q1	$1.06M	Buy	+20,555	New	+$1.04M	0.93%	42

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marvin & Palmer Associates's ABBV Position: Q4 2024 in Review

Marvin & Palmer Associates sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 15,848 shares — an estimated $3.13M sold.

Marvin & Palmer Associates first reported a position in ABBV in Q1 2014 and held it in 2 quarters. The position peaked at $3.13M in Q3 2024. 3,750 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

Marvin & Palmer Associates reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
Marvin & Palmer Associates sold 15,848 AbbVie shares in Q4 2024, an estimated $3.13M.
Marvin & Palmer Associates first reported a position in AbbVie in Q1 2014 and held it in 2 quarters.
Marvin & Palmer Associates's AbbVie position peaked at $3.13M in Q3 2024.
3,750 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Marvin & Palmer Associates's 13F filing for Q4 2024, filed 7 Feb 2025.